PARP Inhibitor BGB-290

DRUG2 trials

Sponsors

University of California, San Francisco, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

GlioblastomaIDH1 Gene MutationIDH1 MutationIDH2 Gene MutationIDH2 MutationLow Grade GliomaMalignant GliomaRecurrent Glioblastoma

Phase 1

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Active, not recruitingNCT03749187

University of California, San FranciscoGlioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation +7

Start: 2019-04-03End: 2029-07-30Target: 78Updated: 2026-03-13

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

CompletedNCT03914742

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsIDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma +2

Start: 2020-02-16End: 2023-10-31Updated: 2025-01-14